The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

African American

23rd Apr 2025

The effect of Relugolix combination therapy in Black/African American women with uterine fibroids: a plain language summary

This summary is about a study that was published in the medical journal The Oncologist in July 2023. The combination of palbociclib with an aromatase inhibitor (AI) was approved by the FDA in 2015 as a treatment for people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer(MBC). However, the effectiveness of palbociclib in African–Americans with MBC is not well studied. The goal of this study was to find out whether adding palbociclib to an AI helped African–Americans with HR+/HER2− MBC live longer.

30th Apr 2024

African American

The effect of Relugolix combination therapy in Black/African American women with uterine fibroids: a plain language summary

A plain language summary looking at the palbociclib/aromatase inhibitor treatment combination in African-Americans with metastatic breast cancer (MBC)